AGE

, Volume 18, Issue 3, pp 97–119 | Cite as

Free radical theory of aging: Alzheimer’s disease pathogenesis

  • Denham Harman
Article

Abstract

Senile dementia of the Alzheimer’s type (SDAT) is the major cause of dementia. SDAT cases can be categorized into two groups: 1) late onset, after about age 60, 90–95 percent of cases; largely nonfamilial, i.e., sporadic, 2) early onset, before about age 60; 5–10 percent of cases, most — if not all — are familial. It is a systemic disorder whose major manifestations are in the brain. The brain lesions in both early and late-onset SDAT are the same as those seen in smaller numbers in normal older individuals.

It is hypothesized that SDAT is caused by increased free radical reaction levels in brain neurons that advance in time patterns of neuronal dysfunction and cell loss. Measures to this end include: 1) mutations in mitochondrial (mt) DNA and/or nuclear (nuc) DNA in a somatic cell early in development that adversely effect mitochondrial function, 2) mutations in maternal mtDNA and/or nucDNA that impair mitochondria in offspring, 3) mutations in the amyloid precursor protein (APP), and 4) increased formation of both normal APP and superoxide dismutase (SOD).

The incidence of SDAT may be decreased by efforts to minimize free radical reactions involved in initiation. The clinical decline of SDAT patients may be slowed by measures which lower the level of more-or-less random deleterious free radical reactions.

Keywords

Dementia Superoxide Dismutase Amyloid Precursor Protein Disease Pathogenesis Neuronal Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Katzman, R.: Alzheimer’s disease. New. Eng. J. Med., 314: 964–973, 1986.PubMedGoogle Scholar
  2. 2.
    Goedert, M., Strittmatter, J., and Roses, A. D.: Risky apoliporotein in brain. Nature, 372: 45–46, 1994.PubMedGoogle Scholar
  3. 3.
    Nalbantoglu, J., Lacoste-Royal, G., and Gauvreau, D.: Genetic factors in Alzheimer’s disease. J. Amer. Geriat. Soc., 38: 564–568, 1990.PubMedGoogle Scholar
  4. 4.
    Breitner, J. C. S., Murphy, E. A., Silverman, J. M., Mohs, R. C., and Davis, K. L.: Age-dependent expression of familial risk in Alzheimer’s disease. Amer. J. Epidemiology, 128: 536–548, 1988.Google Scholar
  5. 5.
    Schellenberg, G. D., Birdd, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J.L., Alonso, M. E., Potter, H., Heston, L. L., and Martin, G. M.: Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science, 258: 668–671, 1992.PubMedGoogle Scholar
  6. 6.
    Levy-Lahad, E. W., Wijsman, E. M., Nemens, E., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., and Schellenberg, G. D.: A familial Alzheimer’s disease locus on chromosome 1. Science, 269: 970–973, 1995.PubMedGoogle Scholar
  7. 7.
    Goate, A., Chartier-Harlin, M.-C., and Mullan, M., et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature, 349: 704–706, 1991.PubMedGoogle Scholar
  8. 8.
    Katzman, R., and Saitoh, T.: Advances in Alzheimer’s disease. FASEB J., 5: 278–286, 1991.PubMedGoogle Scholar
  9. 9.
    Hafner, H.: Epidemiology of Alzheimer’sdisease, in Alzheimer’s Disease: Epidemiology, Neuropathology, Neurochemistry, and Clinics, edited by Maurer, K., Riederer, P.. and Beckmann, H., New York, Springer-Verlag, 1990, pp. 23–39.Google Scholar
  10. 10.
    Baker, A.C., Ko, L.-W., and Blass, J.P.: Systemic manifestations of Alzheimer’s disease. Age, 11: 60–65, 1988.Google Scholar
  11. 11.
    Folstein, M. F., and Bylsma, F. W.: Moncognitive symptoms of Alzheimer’s disease, in Alzheimer Disese, edited by Terry, R. D., Katzmann, R., and Bick, K. L., New York, Raven Press, 1994, pp. 27–40.Google Scholar
  12. 12.
    Reisberg, B.: Clinical presentation, diagnosis, and symptomatology of age-associated cognitive decline and Alzheimer’s disease, in Alzheimer’s Disease, edited by Reisberg, B., New York, The Free Press, 1983, pp. 173–187.Google Scholar
  13. 13.
    Berg, L., and Morris, J. C., Diagnosis, in Alzheimers Disease, edited by Terry, R. D., Katzman, R., and Bick, K. L, New York, Raven Press, pp. 9–25.Google Scholar
  14. 14.
    Peterson, C., and Goldman, J. E.: Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer’s donors. Proc. Natl. Acad. Sci., USA, 83: 2758–2762, 1986.PubMedGoogle Scholar
  15. 15.
    Nitsch, R. M., Blusztajn, J. K., Pittas, A. G., Slack, B. E., Growdon, J. H., and Wurtman, R.J.: Evidence for a membrane defect in Alzheimer’s disease brain. Proc. Natl. Acad. Sci., USA, 89: 1671–1675, 1992.PubMedGoogle Scholar
  16. 16.
    Bossman, G. J. C. G. M., Bartholomeus, I. G. P., and deGrip, W.J.: Alzheimers disease and cellular aging: membrane-related events as clues to primary mechanisms. Gerontol., 37: 95–112, 1991.Google Scholar
  17. 17.
    Parker, Jr., W. D., Filley, C. M., and Parks, J. K.: Cytochrome oxidase deficiency in Alzheimer’s disease. Neurol., 40: 1302–1303, 1990.Google Scholar
  18. 18.
    Katzman, R., and Jackson, J. E.: Alzheimer disease: basic and clinical advances. J. Amer. Geriatrics Soc., 39: 516–525, 1991.Google Scholar
  19. 19.
    McKee, A. C., Kosik, K. S., and Kowall, N. W.: Neuritic pathology and dementia in Alzheimer’s disease. Ann. Neurol., 30: 156–165, 1991.PubMedGoogle Scholar
  20. 20.
    Terry. R. D.: Ultrastructural alterations in senile dementia, in Alzheimer’s Disease: Senile Dementia and Related Disorders, edited by Katzman. R., Terry, R. D., and Bick, K. L., New York, Raven Press, 1978, pp. 375–382.Google Scholar
  21. 21.
    Wisniewski, H. M.. and Merz, G. S.: Neuropathology of the aging brain and dementia of the Alzheimer type, in Aging 2000: Our Health Care Destiny, Vol. 1: Biomedical Issues, edited by Gaitz, C. M., and Samorajski, T., New York, Springer-Verlag, 1983. pp. 231–243.Google Scholar
  22. 22.
    Wisniewski, H. M, and Terry, R. D.: Morphology of the aging brain, human and animal. Progr. Brain Res., 40: 167–186, 1973.Google Scholar
  23. 23.
    Terry, R. D., Masliak. E., and Hansen, L. A., Structural basis of the cognitive alterations in Alzheimer disease, edited by Terry, R. D., Katzman, R., and Bick, K. D., New York, Raven Press, pp. 179–196.Google Scholar
  24. 24.
    Crystal, H., Dickson, D., and Fuld, P., et. al.: Clinico-patbologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease. Neurol., 38: 1682–1687, 1988.Google Scholar
  25. 25.
    Arriagada, P. V., Marzloff, K., and Hyman, B. T.: Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurol., 42: 1681–1688, 1992.Google Scholar
  26. 26.
    Goedert, M.: Tau protein and the neurofibrillary pathologhy of Alzheimer’s disease. Trends Neurol. Sci., 16:460–465, 1993.Google Scholar
  27. 27.
    Braak, H. and Braak, E.: Neuropathologlcat staging of Alzheimer-related changes. Acta Neuropathol., 82: 239–259, 1991.PubMedGoogle Scholar
  28. 28.
    Braak, H., and Braak, E.: Morphology of the cerebral cortex in relation to Alzheimer’s dementia, in Alzheimers disease: Epidemiology, Neuropathology, Neurochemistry, and Clinics, edited by Maurer, K., Riederer, P., and Beckmann, H., New York, Springer-Verlag, 1990, pp. 85–91.Google Scholar
  29. 29.
    Arriagada, P. V., Growdon, H. H., Hedley-Whyte, E. T., and Hyman, B. T.: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurol., 42: 631–639, 1992.Google Scholar
  30. 30.
    Masliah, E., Terry, R. D., DeTeresa, R. M., and Hansen, L.A.: Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer’s disease. Neurosci. Lett., 103: 234–239 1989.PubMedGoogle Scholar
  31. 31.
    DeKosky, S. T., and Scheff, S. W.: Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol., 27: 457–464, 1990.PubMedGoogle Scholar
  32. 32.
    Samuel, W., Terry, R. D., De Terresa, R., Butters, N., and Masliak, E.: Clinical correlates of cortical and nucleus basatis pathology in Alzheimer dementia. Arch. Neurol, 51: 772–778, 1994.PubMedGoogle Scholar
  33. 33.
    Nishmimura, Mm., Tomimoto, H., Suenaga, T., Namba, Y., Ikeda, K., Akiguchi, I., and Kimura, J.: Imunocytochemical characterization of glial fibrillary tangles in Alzheimer’s disease brain. Amer. J. Pathol., 146: 1052–1058, 1995.Google Scholar
  34. 34.
    Pearsor. R. C. A., Esiri, M. M., Hiorns, R. W., Wilcock. G.K., and Powell, T. P. S.: Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer’s disease. Proc. Natl. Acad. Sci., USA, 82: 4531–4534, 1985.Google Scholar
  35. 35.
    Arendt, T., Bigl, V., Tennsted, A., and Arendt, A.: Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer’s disease. Neurosci., 14: 1–14, 1985.Google Scholar
  36. 36.
    Terry, R. D., Bonatas, N. K., and Weiss, M.: Ultrastructural studies in Alzheimer’s presenile dementia. Amer. J. Pathol., 44: 269–281, 1964.Google Scholar
  37. 37.
    McGeer. P. L., and Rogers, J.: Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurol., 42: 447–449, 1992.Google Scholar
  38. 38.
    Lampert. P., Blumberg, J. M., and Pentschew, A.: An electron microscopic study of dystrophic axons in the gracile and cuneate nuclei of vitamin E-deficient rats. J. Neuropathol. Exper. Neurol., 23: 60–77, 1964.Google Scholar
  39. 39.
    Cataldo. A. M., and Nixon, R.A.: Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci., USA, 87: 3861–3865, 1990.PubMedGoogle Scholar
  40. 40.
    Cataldo A. M., Paskevich, P. A., Kominami, E., and Nixon, R.A.: Lysomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer’s disease. Proc. Natl. Acad. Sci., USA, 88: 10998–11002, 1991.Google Scholar
  41. 41.
    Tennent. G. A., Lovat, L. B., and Pepys, M. B.: Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer diease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA, 92: 4299–4303, 1995.PubMedGoogle Scholar
  42. 42.
    Haga, S. Ikeda, K., Sato, M., and Ishii, T.: Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res., 601: 88–94, 1993.PubMedGoogle Scholar
  43. 43.
    Stopa, E. G., Gonzalez, A.-M., Chorsky, R., Corona, R. J., Alvarez, J. Bird, E. D., and Baird, A.: Basic fibroblast growth factor in Alzheimer’s disease. Biochem. Biophysic. Res. Commun., 171: 690–696, 1990.Google Scholar
  44. 44.
    Masliah, E., Cole, G. M., Hansen, L. A., Mallory, M., Albright, T., Terry, R. D., and Saitoh, T.: Protein kinase C alteration is an early biochemical marker in Alzheimer’s disease. J. Neurosci., 11: 2759–2767, 1991.PubMedGoogle Scholar
  45. 45.
    Hyman, B. T., Van Hoesen, G. W, Damasio, A. R, and Barnes, C. L.: Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science, 225: 1168–1170, 1984.PubMedGoogle Scholar
  46. 46.
    Ball, M. J., Hachinski, V., Fox, A., Kirshen, A. J., Fisman, M., Blume, W., Kral, V. A., and Fox, H.: A new definition of Alzheimer’s disease: a hippocampal dementia. Lancet, 1: 14–16, 1985.PubMedGoogle Scholar
  47. 47.
    Braak, H., and Braak, E.: Entorhinal lesions in dementia, in Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, edited by Iqbal, K., McLachlan, D. R. C., Winblad, B., and Wisniewski, H. M., New York, John Wiley, 1990, pp. 91–97.Google Scholar
  48. 48.
    Mann, D. M.: The neuropathology of Alzheimer’s disease: a review with pathogenic, aetiological and therapeutic considerations. Mech. Ageing Dev., 31: 213–255, 1985.PubMedGoogle Scholar
  49. 49.
    Gray, E. G., Paula-Barbosa, M., and Roher, A.: Alzheimer’s disease: paired helical filaments and cytomembranes. Neuropathol. Appl. Neurobiol., 13: 91–110, 1987.PubMedGoogle Scholar
  50. 50.
    Friede, R. L: The relation of the formation of lipofuscin to the distribution of oxidative enzymes n the human brain. Acta Neuropathol., 2: 113–125, 1962.Google Scholar
  51. 51.
    Reddy, K., Fletcher, B., Tappel, A. L.: Measurement and spectral characteristics of fluorescent pigments in the tissues of rats as a function of polyunsaturated fats and vitamin E. J. Nutr., 103: 908–015, 1973.PubMedGoogle Scholar
  52. 52.
    Brizzee, K. R., Eddy, D. E., Harman, D., and Ordy, J.M.: Free radical theory of aging: effect of dietary lipids onlipofuscin accumulation in the hippocampus of rats. Age, 7: 9–15, 1984.Google Scholar
  53. 53.
    Eddy, D. E., and Harman, D.: Rat brain fatty acid composition: effect of dietary fat and age. J. Gerontol. 30: 647–654, 1975.PubMedGoogle Scholar
  54. 54.
    Crawford, M. A., and Sinclair, A. J.: Nutritional influences in the evolution of mammalian brain, in Lipids, Malnutrition & the Developing Brain, edited byElliott, K., and Knight, J., Amsterdam, Elsevier/Excerpta/North-Holland, 1972, pp. 267–287.Google Scholar
  55. 55.
    Eddy, D. E., and Harman, D.: Free radical theory of aging: effect of age, sex and dietary precursors on rat brain docosahexanoic acid. J. Amer. Geriatr. Soc., 25: 220–229, 1977.Google Scholar
  56. 56.
    Tinoco, J., and Williams, M. A., Hincenbergs, I., Lyman, R. L.: Evidence for nonessentiality of linolenic acid in the diet of the rat. J. Nutr., 101: 937–946, 1971.PubMedGoogle Scholar
  57. 57.
    Walker, R. L.: Maternal diet and brain fatty acids in young rats. Lipids, 2: 497–500, 1967.Google Scholar
  58. 58.
    Tamai, Y., Matsukawa, S., and Satake, M.: Lipid composition of newe cell perikarya. Brain Res., 26: 149–157, 1971.Google Scholar
  59. 59.
    Cotman, C., Blank, M. L., Moehl, A., and Synder, F.: Lipid composition of synaptic plasma membranes isolated from rat brain by zonal centrifugation. Biochem., 8: 4606–4612, 1969.Google Scholar
  60. 60.
    Hubbard, B.M., and Anderson, J.M.: Sex difference in age-related brain atrophy. Lancet 1: 1447–1446, 1983.PubMedGoogle Scholar
  61. 61.
    Harman, D.: Lipofuscin and ceroid formation: the cellular recycling system, in Lipofuscin and Ceroid Pigments, edited by Porta, E.A., New York, Plenum Press, 1990, pp. 3–15.Google Scholar
  62. 62.
    Mayer, R. J., Landon, M., Lazlo, L., Lennox, G., and Lowe, J.: Protein processing in lysomes: the new therapeutic target in neurodegenerative disease. Lancet, 340: 156–159, 1992.PubMedGoogle Scholar
  63. 63.
    Nixon, R. A., Cataldo, A. M., Paskevich, P. A., Hamilton, D.J., Wheelock, T. R., and Andrews, L. K.: The lysosomal system in neurons: involvement at multiple stages of Alzheimer’s disease pathogenesis. Ann. New York Acad. Sci., 674: 65–88, 1992.Google Scholar
  64. 64.
    Stadtman, E. R.: Covalent modification reactions are marking steps in protein turnover. Biochem., 29: 6323–6331, 1990.Google Scholar
  65. 65.
    Stadtman, E. R.: Oxidation of protein by mixed-function oxidation systems: implication in protein turnover, ageing and neutrophil function. Trends Biochem. Sci., 11: 11–12, 1986.Google Scholar
  66. 66.
    Stadtman, E. R.: Metal ion-catalyzed oxidation of proteins: biochemical mechanisms and biological consequences. Free Radical Biol. Med., 9: 315–325, 1990.Google Scholar
  67. 67.
    Stadtman, E. R., and Oliver, C. N.: Metal-catalyzed oxidation of proteins: physiological consequences. J. Biol. Chem., 266: 2005–2008, 1991.PubMedGoogle Scholar
  68. 68.
    Stadtman, E.R.: Protein oxidation and aging. Science, 257: 1220–1224, 1992.PubMedGoogle Scholar
  69. 69.
    Davies, K. J.A.: Protein damage and degradation by oxygen radicals. J. Biol. Chem., 262: 9895–9901, 1987.PubMedGoogle Scholar
  70. 70.
    Rivett, A. J., and Hare, J. F.: Mixed function oxidation of glutamine synthetase leads to its rapid degradation in vitro and after fusion-mediated injection into hepatoma cells. Biochem. Soc. Trans., 14: 643–644, 1986.Google Scholar
  71. 71.
    Starke-Reed, P. E., and Oliver, C. N.: Protein oxidation and proteolysis during aging and oxidative stress. Arch. Biochem. Biophys., 275: 559–567, 1989.PubMedGoogle Scholar
  72. 72.
    Marzella, L., and Glaumann, H.: Autophagy, micro-autophagy and crinophagy as mechanisms for protein degradation, in Liposomes: Their Role in Protein Breadkdown, edited by Glaumann, H., and Ballard, F. J., New York, Academic Press, 1987, pp. 319–366.Google Scholar
  73. 73.
    Roots, B. I.: Neurofilament accumulaton induced in synapses by leupeptin. Science, 224: 971–972, 1983.Google Scholar
  74. 74.
    Ivy, G. O., Schottler, F., Wenzel, J., Baudry, M., and Lynch, G.: Inhibitors of lysosomal enzymes: accumulation of lipofuscin-like dense bodies in brain. Science, 226: 985–987, 1984.PubMedGoogle Scholar
  75. 75.
    Takauchi, S., and Miyoski, K.: Degeneration of neuronal processes in rats induced by a protease inhibitor, leupeptin. Acta Neuropathol., 78: 380–387, 1969.Google Scholar
  76. 76.
    Harman, D.: Free radical theory of aging: role of free radicals in the origination and evolution of life, aging, and disease processes, in Free Radicals, Aging, and Degenerative Diseases, edited by Johnson, Jr., J.E., Walford, R., Harman, D., and Miquel, J., New York, Alan R. Liss, 1986, pp. 3–49.Google Scholar
  77. 77.
    Harman, D.: Free radical theory of aging. Mutation Res., 275: 257–266, 1992.PubMedGoogle Scholar
  78. 78.
    Sagai, M., and Ichinose. T.: Age-related changes in lipid peroxidation as measured by ethane, ethylene, butane and pentane in respired gases by rats. Life Sci., 27: 731–738, 1980.PubMedGoogle Scholar
  79. 79.
    Linnane, A.W., Marzukj, S., Ozawa, T., and Tanaka, M.: Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet, 1: 642–645, 1989.PubMedGoogle Scholar
  80. 80.
    Zaman, Z., Roche, S., Fielden, P., Frost, P. G., Niriella, D. C., and Cayley, A. C. D.: Plasma concentrations of vitamins A and E and carotenoids in Alzheimer’srdisease. Age and Ageing, 21: 91–94, 1992.PubMedGoogle Scholar
  81. 81.
    Schipper, H. M., Cisse, S., and Stopa, E. G.: Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol, 37: 758–768, 1995.PubMedGoogle Scholar
  82. 82.
    Smith, M. A., Kutty, R. K., Richey, P. L., Yan, S.-D., Stern, D., Chader, G. J., Wiggert, B., Petersen, R. B., and Perry, G.: Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer’s disease. Amer. J. Pathol., 145: 42–47, 1994.Google Scholar
  83. 83.
    Applegate, L. A., Luscher, P., and Tyrrell, R. M.: Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res., 51: 974–978, 1991.PubMedGoogle Scholar
  84. 84.
    Sims, N. R., Bowen, D. M., Neary, D., and Davison, A. N.: Metabolic processes in Alzheimer’s disease: adenine nucleotide content and production of 14CO2 from (U-14C)glucose in vitro in human neocortex. J. Neurochem., 41: 1329–1324, 1983.PubMedGoogle Scholar
  85. 85.
    Khansari, N., Whitten, H. D., Chou, Y. K., and Fudenberg, H. H.: Immunological dysfunction in Alzheimer’s disease. J. Neuroimmunol., 7: 279–285, 1985.PubMedGoogle Scholar
  86. 86.
    Martins, R. N., Harper, C. G., Stokes, G. B., and Masters, C. L.: Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. J. Neurochem., 46: 1042–1045, 1986.PubMedGoogle Scholar
  87. 87.
    Saito, K.-I., Elce, J. S., Hamos, J. E., and Nixon, R. A.: Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA, 90:2628–2632, 1993.PubMedGoogle Scholar
  88. 88.
    Nixon, R. A., and Cataldo, A. M.: Free radicals, proteolysis, and the degeneration of neurons in Alzheimer disease: how essential is the β-amyloid link? Neurobiol. Aging, 15: 463–469, 1994.PubMedGoogle Scholar
  89. 89.
    Perry, T. L., Yong, V. W., Bergeron, C., Hansen, S., and Jones, K.: Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer’s disease. Ann. Neurol. 21: 331–336, 1987.PubMedGoogle Scholar
  90. 90.
    Goedert. M., Spillantini, M.S. Jakes, R., Rutherford, D., and Crowther, R.: Multiple isoforms of human microt uble-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron, 3: 519–526, 1989.PubMedGoogle Scholar
  91. 91.
    Himmler. A.,: Structure of the bovine tau gene: alternatively spliced transcrits generate a protein family. Mol. Cell. Biol., 9: 1389–1396, 1989.PubMedGoogle Scholar
  92. 92.
    Butner, K.A., and Kirschner, M.W.: Tau protein binds to microtubules through a flexible array of distribured weak sites. J. Cell Biol., 115: 717–730, 1991.PubMedGoogle Scholar
  93. 93.
    Wille, H.. Drewes, G., Biernat, J., Mandelkow, E.-M., and Mandelkow, E.: Alzheimer-like paired helical filaments and antiparallel dimers formed from mic rotubule-associated protein tau in vitro. J. Cell Biol.. 118: 573–584, 1992.PubMedGoogle Scholar
  94. 94.
    Ksiezak-Reding, H., Liu. W.-K, and Yen, S.-H.: Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res., 597: 209–219, 1992.PubMedGoogle Scholar
  95. 95.
    Gustke, N., Steiner, B., Mandelkow, E.-M., Biernat, J., Meyer. H.E., Goedert, M., and Mandelkow, E.: The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. Fed. Europ. Biochem. Soc., 307: 199–205, 1992.Google Scholar
  96. 96.
    Steiner, B., Mandelkow, E.-M., Biernat, J., Gustke, N., Meyer, H. E., Schmidt, B., Mieskes, G., Soiling, H.D., Drechsel, D., Kirschner, M. W., Goedert, M., and Mandelkow, E.: Phosphorylation of microtubule-associated protein tau: identification of the site for Ca2+-calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles. EMBO J., 9: 3539–3544, 1990.PubMedGoogle Scholar
  97. 97.
    Hyman, B. T., Elvhage, T. E., and Reiter, J.: Extracellular signal regulated kinases: localization of protein and mRNA in the human hippocampal formation in Alzheimer’s disease. Amer. J. Pathol., 144: 565–572, 1994.Google Scholar
  98. 98.
    Goedert. M., Cohen, E.S., Jakes, R., and Cohen, P.: p42 map kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Fed. Europ. Biol. Soc., 312: 95–99, 1992.Google Scholar
  99. 99.
    Goedert. M., Spillantini, M.G., Cairns, N.J., and Crowther. R. A.: Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron, 8: 159–168, 1992.PubMedGoogle Scholar
  100. 100.
    Monejo de Garcini, E., Carrascosa, J. L., Correas, I., Nieto. A., and Avila, J: Tau factor polymers are similar to paired helical filaments of Alzheimer’s disease. Fed. Europ. Biochem. Soc., 236: 150–154, 1988.Google Scholar
  101. 101.
    Strittmatter, W. J., Weisgraber, K. H., Goedert, M., Saunders, A.M., Huang, D., Corder, E. H., Dong, L.-M., Jakes, R., Alberts, M. J., Gilbert, J. R., Han, S.-H., Hullette, C., Einstein, G., Schmechel, D. E., Pericak-Vance, M. A., and Roses. A.D.: Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exper. Neurol., 125: 163–171, 1994.Google Scholar
  102. 102.
    Yan, S.-D., Chen, X., Schmidt, A.-M, Brett, J., Goodman., G., Zou, Y.-S., Scott, C. W., Caputo, C., Frappier, T., Smith, M. A., Perry, G., Yen, S.-H., and Stem, D.: Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA, 91: 7787–7791, 1994.PubMedGoogle Scholar
  103. 103.
    Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Titani, T., and Ihara, Y.: Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron, 10: 1151–1160, 1993.PubMedGoogle Scholar
  104. 104.
    Dean, R. T.: A mechanism for accelerated degradation of intracellular proteins after limited damage by free radicals. FEBS Lett., 220: 278–282, 1987.PubMedGoogle Scholar
  105. 105.
    Vogelsang, G. D., Zemlan, F. P., and Dean, G. E.: Hyperpurification of paired helical filaments reveals elevations in hydroxyproline content and a core structure related peptide fragment, in Progress in Clinical and Biological Research. Vol. 317. AIzheimer’s Disease and ReLated Dsorders, edited by Iqbal, K. Wisniewski, H. M., and Winblad, B., New York, Alan R. Liss, 1989, pp. 791–800.Google Scholar
  106. 106.
    Mirabelli, F., Salis, A., Vairetti, M., Bellomo, G., Thor, H., Orrenius, S.: Cytoskeletal alterations in human plateletes exposed to oxidative stress are mediated by oxidative and Ca2+ mechanisms. Arch. Biochem. Biophy., 270: 478–489, 1989.Google Scholar
  107. 107.
    Thompson, C. B.: Apoptosis in the pathogenesis and treatment of disease. Science, 267: 1456–1462, 1995.PubMedGoogle Scholar
  108. 108.
    Orrenius, S., McConkey, D. S., Bellomo, G., Nicotera, P.: Role of Ca2+ in toxic cell killing. Trends Pharmacol. Sci., 10: 281–285, 1989.PubMedGoogle Scholar
  109. 109.
    Orrenius, S., McConkey, D. J., and Nicotera, P.: Role of calcium in toxic and programmed cell death. Adv. Exper. Med. Biol., 283: 419–425, 1991.Google Scholar
  110. 110.
    Nicotera, P., Bellomo, G., and Orrenius, S.: The role of Ca2+ in cell killing. Chem. Res. Toxicol., 3: 484–494, 1990.PubMedGoogle Scholar
  111. 111.
    Lipton, S. A., and Rosenberg, P. A.: Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J.Med., 330: 613–622, 1994.PubMedGoogle Scholar
  112. 112.
    Coyle, J. T., and Puttfarcken, P.: Oxidative stress, glutamate, and neurodegenerative disorders. Science, 262: 689–695, 1993.PubMedGoogle Scholar
  113. 113.
    Beal, M. F., Hyman, B. T., and Koroshetz, W.: Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? TrendsNeurol. Sci., 16, 125–131, 1993.Google Scholar
  114. 114.
    Bensimon, G., Lacomblez, L., Meininger, V., and the ALS/Riluzole Study Group. A controlled trial of dluzole in amyotrophic lateral sclerosis. N. Engl. J. Med., 330: 585–591, 1994.PubMedGoogle Scholar
  115. 115.
    Mattson, M. D., Rychlik, B., and Engle, M. G.: Possible involvement of calcium and inositol phospholipid signaling pathways in neurofibdllary degeneration, in Alzheimer’s Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, edited by Iqbal, K., McLachlan, D. R. C., Winblad, B., Wisniewski, H. M., New York, John Wiley& Sons, 1990, pp. 191–198.Google Scholar
  116. 116.
    Floyd, R. A., Zaleska, M. M., and Harmon, H. J.: Possible involvement of iron and oxygen free radicals in aspects of aging in brain, in Free Radicals in Molecular Biology, Aging, and Disease, edited by Armstrong, D., Sohal, R. S., Cutler, R. G., and Slater, T. E., New York, Raven Press, 1984, pp. 143–161.Google Scholar
  117. 117.
    Schmidt, M. L., DiDario, A. G., Lee, V., M.-Yjuvdot, Trojanowski, J. Q.: An extensive network of PHFSô-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease. FEBS Lett., 344: 69–73, 1994.PubMedGoogle Scholar
  118. 118.
    Haass, C., Schlossmacher, M. G., Hung, A. Y., et al.: Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature, 359: 322–325, 1992.PubMedGoogle Scholar
  119. 119.
    Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., et al.: Isolation and quantification of soluble Alzheimer’s-peptide from biological fluids. Nature, 359: 325–327, 1992.PubMedGoogle Scholar
  120. 120.
    Shoji, M., Golde, T. E., and Ghiso, J., et al.: Production of the Alzheimer amyloid β-protein by normal proteolytic processing. Science, 258:126–129, 1992.PubMedGoogle Scholar
  121. 121.
    Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J., and Younkin, S. G.: Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science, 255: 728–730, 1992.PubMedGoogle Scholar
  122. 122.
    Haass, C., Koo, E. H., Mellon, A., Hung, A. Y., and Selkoe, D.J.: Targeting of ce!l-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature, 357: 500–503, 1992.PubMedGoogle Scholar
  123. 123.
    Isenman, L. D., Dice, J. F.: Secretion of intact proteins and peptide fragments by lysosomal pathways of protein degradation. J. Biol. Chem., 264: 21591–21596, 1989.Google Scholar
  124. 124.
    Buktenica, S., Olenick, S. J., Salgia, R., and Frankfater, A.: Degradation and regurgitation of extracellular proteins by cultured mouse peritoneal macrophages and baby hamster kidney fibroblasts. J. Biol. Chem., 262: 9469–9476, 1987.PubMedGoogle Scholar
  125. 125.
    Kawai, M., Cras, P., Richey, P., Tabaton, M., Lowery, D. E., Gonzalez-DeWhitt, P. A., Greenberg, B. D., Gambetti, P., and Perry, G.: Subcellularlocalization of amyloid precursor protein in senile plaques of Alzheimer’s disease. Amer. J. Pathol., 140: 947–958, 1992.Google Scholar
  126. 126.
    Johnstone, E. M., Chaney, M. O., Norris, F. H., Pasgual, R., and Little, S. P.: Conservation of the sequence of Alzheimer’s disease amyloid peptide in dog, polar bear and five other mammals by cross-species potymerase chain reaction analysis. Mol. Brain Res. 10: 299–305, 1991.PubMedGoogle Scholar
  127. 127.
    Hyman, B. T., Marzloff, K., and Arriagada, P. V.: The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution. J.Neuropathol. Exper. Neurol., 52: 594–600, 1993.Google Scholar
  128. 128.
    Jarrett, H. T., and Lansbury, Jr., P. T.: Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell, 73: 1055–1058, 1993.PubMedGoogle Scholar
  129. 129.
    Evans, K. C., Berger, E. P., Cho, C.-G., Weisgraber, K.H., and Lansbury, Jr., P. T.: Apoliporotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 92: 763–767, 1995.PubMedGoogle Scholar
  130. 130.
    Jarrett, J. T., Berger, E. P., and Lansbury, Jr., P. T.: The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry, 32: 4693–4697, 1993.PubMedGoogle Scholar
  131. 131.
    Barrows, C. J., and Zagorski, M. G.: Solution structure of peptide and its constituent fragments: relation to amyloid deposition. Science, 253: 179–182, 1991.Google Scholar
  132. 132.
    Burdick, D., Soreghan, B., and Kwon, M. et al.: Assembly and aggregation properties of synthetic Alzheimer’s A4/amyloid peptide analogs. J. Biol. Chem., 267: 546–554, 1992.PubMedGoogle Scholar
  133. 133.
    Hilbich, C., Kisters-Wolke, B., Reed, J., Masters, C. L., Beyreuther, K.: Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer’s disease. J. Mol. Biol., 218: 149–163, 1991.PubMedGoogle Scholar
  134. 134.
    Kirschner, D. A., Inouge, H., Duffy, L. K., et al.: Synthetic peptide homologous to β-protein from Alzheimer’s disease forms amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci., USA, 84: 6953–6957, 1987.PubMedGoogle Scholar
  135. 135.
    Bush, A. L., Pettingel, Jr., W. H., d. Paradis, M., and Tanzi, R. E.: Modulation of Aβ Adhesiveness and Secretase Site Clevage by Zinc. J. Biol. Chem., 269: 12152–12158, 1994.Google Scholar
  136. 136.
    Mantyh, P. W., Ghilardi. J. R., Rogers, S., DeMaster. E., Allen, C. J.. Stimson, E. R., and Maggio, J. E.: Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J. Neurochem., 61: 1171–1174. 1993.PubMedGoogle Scholar
  137. 137.
    Snow, A. D.. Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K.. Mizutani, A., Arai, M., Schreier, W. A., and Morgan, D. G.: An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain. Neuron, 12: 219–234, 1994.PubMedGoogle Scholar
  138. 138.
    Vitek, M. P.. Bhattacharya, K., Glendening, J. M., Stopa, E.. Vlassara, H., Bucala, R., Manogue, K., and Cerami. A.: Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91: 4766–4770, 1994.PubMedGoogle Scholar
  139. 139.
    Ma, J., Yee, A., Brewer, Jr., H. B., Das, S., and Potter, H.: Amyloid-associated proteins β 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein assembly of Alzheimer β-protein into filaments. Nature, 372: 92–94, 1994.PubMedGoogle Scholar
  140. 140.
    Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L.-M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., and Roses, A. D.: Binding of human apolipoprotein E to synthetic β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA, 90: 8098–8102, 1993.PubMedGoogle Scholar
  141. 141.
    Sanan, D. A., Weisgraber, K. H., Russell, S. J., Mahley, R. W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., Roses, A. D., and Strittamtter, W. J.: Apolipoprotein E associates with β amyloid peptide of Alzheimer’s disease to form novel monofibrils: isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest., 94: 860–869 1994.PubMedGoogle Scholar
  142. 142.
    Davies, C. A., and Mann, D. M. A.: Is the “preamyloid” of diffuse plaques in Alzheimer’s disease really nonfibrillar? Amer. J. Pathol., 143: 1594–1605, 1993.Google Scholar
  143. 143.
    Younkin. S. G:: Evidence that Aβ42 is the real culprit in Alzheimer’s disease. Ann. Neurol., 37: 287–288. 1995.PubMedGoogle Scholar
  144. 144.
    Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang. R., Cotter, R. J., Reardon, I. M., Zurcher-Neely, H. A., Heinrikson, R. L., Ball, M. J., and Greenberg, B. D.: Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J. Biol. Chem., 268: 3072–3083, 1993.PubMedGoogle Scholar
  145. 145.
    Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin. Y. Y., Biemann, K. and Iqbal, K.: Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch. Biochem. Biophys., 301: 41–52, 1993.PubMedGoogle Scholar
  146. 146.
    Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and Ihara, Y.: Visualization of Aβ 42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron, 13: 45–53, 1994.PubMedGoogle Scholar
  147. 147.
    Iwatsubo, T., Mann, D. M. A., Odaka, A., Suzuki, N., and Ihara, Y: Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann. Neurol., 37: 294–299, 1995.PubMedGoogle Scholar
  148. 148.
    Dyrks, T., Dyrks, E, Hartmann, T., Masters, C., and Beyreuther, K.: Amyloidogenicity of βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem., 267: 18210–18217, 1992.Google Scholar
  149. 149.
    Van Gool, D., De Strooper, B., Van Leuven, F., Triau, E., and Dom, R.: β2-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer’s disease. Neurobiol. Aging, 14: 233–237, 1993.PubMedGoogle Scholar
  150. 150.
    Merrill, J. E., and Jonakait, G. M.: Interactions of the nervous and immune systems in development, normal brain homeostasis, and disease. FASEB J., 9: 611–618, 1995.PubMedGoogle Scholar
  151. 151.
    Hensley, K. H., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., and Butterfield, D. A.: A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance β to Alzheimer disease. Proc. Natl. Acad. Sci. USA, 91: 3270–3274, 1994.PubMedGoogle Scholar
  152. 152.
    Butterfield, D. A., Hensley, K., Harris, M., Mattson, M. and Carney, J.: β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer’s disease. Biochem. Biophys. Res. Commun., 200: 710–715, 1994.PubMedGoogle Scholar
  153. 153.
    Terry, R. D., Peck, A., DeTeresa, R., Schechter, R., and Horoupian, D. S.: Some morphometric aspects of the brain in senile dementia of the Alzherimer type. Ann. Neurol., 10: 184–192, 1981.PubMedGoogle Scholar
  154. 154.
    Steller, H.: Mechanisms and genes of cellular suicide. Science, 267: 1445–1449, 1995.PubMedGoogle Scholar
  155. 155.
    Cleveland, J. L., and Ihle, H. N.: Contenders in FasL/TNF death signalling. Cell, 81: 479–482, 1995.PubMedGoogle Scholar
  156. 156.
    Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., and Korsmeyer, S. J.: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241–251, 1993.PubMedGoogle Scholar
  157. 157.
    Oltval, Z., N., and Korsmeyer, S. J.: Checkpoints of dueling dimers foil death wishes. Cell, 79: 189–192, 1994.Google Scholar
  158. 158.
    Lassmann, H., Bancher, C., Breitschopf, H., Wegiel, J., Bobinki, M., Jellnger, K., and Wisniewski, H. M.: Cell death in Alzheimer’s disease evaluated by DNA fragmentation in situ. Acta Neurol., 89: 35–41, 1995.Google Scholar
  159. 159.
    Oberhammer, F., Wilson, J. W., Dive, C., Morris, I. D., Hickman, J. A., Wakeling, A. E., Walker., P. R., and Sikorska, M.: Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments priorto or in the absence of intemucleosomal fragmentation. EMBO J., 12: 3679–3684, 1993.PubMedGoogle Scholar
  160. 160.
    Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G.. and Cotman, C. W.: Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci., 13: 1676–1687. 1993.PubMedGoogle Scholar
  161. 161.
    Simmons, L. K., May, P. C., Tomaselli, K. J., Rydel. R. E., Fuson, K. S., Brigham, E. F., Wright, S., Lieberburg, I., Becker, G. W., Brems, D. N., and Li. W. Y.: Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Molecular Pharmacol., 45: 373–375, 1994.Google Scholar
  162. 162.
    Lorenzo, A., and Yankner, B. A.: β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Natl. Acad. Sci. USA, 91: 12243–12247, 1994.Google Scholar
  163. 163.
    Schubert, D., Behl, C., Lesley, R., Brack, A., Dargusch, R., Sagara, Y., and Kimura, H.: Amyloid peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci. USA, 92: 1989–1993, 1995.PubMedGoogle Scholar
  164. 164.
    Behl, C, Davis, J. B., Lesley, R., and Schubert, D.: Hydrogen peroxide mediates amyloid β protein toxicity. Cell, 77: 817–827, 1994.PubMedGoogle Scholar
  165. 165.
    Loo, D. T., Copani, A., Pike, C. J., Whittemore, E. R., Walencewicz, A. J., and Cotman, C. W.: Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA, 90: 7951–7955, 1993.PubMedGoogle Scholar
  166. 166.
    Behl, C., Davis, J. B., Klier, F. G., and Schuber, D.: Amyloid β peptide induces necrosis rather than apoptosis. Brain Res., 645: 253–264, 1994.PubMedGoogle Scholar
  167. 167.
    Behl, C., Davis, J., Cole, G. M., and Schubert, D.: Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem. Biophys. Res. Commun., 186: 944–950, 1992.PubMedGoogle Scholar
  168. 168.
    Bugiani, O., Giaccone, G., Frangione, B., Ghetti, B., and Tagliavini, F.: Alzheimer patients: preamyloid deposits are more widely distributed than senile plaques throughout the central nervous system. Neurosci. Lett., 103: 263–268, 1989.PubMedGoogle Scholar
  169. 169.
    Masliah, E., Terry, R. D., Mallory, M., Alford, M., and Hansen, L. A.: Diffuse plaques do not accentuate synapse loss in Alzheimer’s disease. Amer. J. Pathol., 137: 1293–1297, 1990.Google Scholar
  170. 170.
    Yamaguchi, H., Nakazato, Y., Shoji, M., Takatama, M., and Hirai, S.: Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques. Acta Neuropathol., 82: 13–20, 1991.PubMedGoogle Scholar
  171. 171.
    Verga. L., Frangione, B., Tagliavini, F., Giaccone, G., Migheli, A., and Gugiani, O.: Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci. Lett., 105: 294–299, 1989.PubMedGoogle Scholar
  172. 172.
    Mann, D. M. A., and Esiri, M. M.: The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome. J. Neurol. Sci., 89: 169–179, 1989.PubMedGoogle Scholar
  173. 173.
    Boje, K. M., and Arora, P. K.: Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res., 587: 250–256, 1992.PubMedGoogle Scholar
  174. 174.
    Chao, C. C., Hu, S., Molitor, T. W., Shaskan, E. G., and Peterson, P. K.: Activated microglial mediate neuronal cell injury via a nitric oxide mechanism. J. Immunol., 2736–2741, 1992.Google Scholar
  175. 175.
    Meda, L., Cassatella, M. A., Szendrel, G. I., Otvos Jr., L., Baron, P., Villalba, M., Ferrari, D., and Rossi, F.: Activation of microglial cells by β-amyloid protein and interferon-β. Nature, 374: 647–650, 1995.PubMedGoogle Scholar
  176. 176.
    Traugott, U., and Lebon, P.: Interferon-ã and la antigen are present on astrocytes in active chronic multiple sclerosis lesions. J. Neurol. Sci., 84: 257–264, 1988.PubMedGoogle Scholar
  177. 177.
    Chao, C. C., Molitor, T.W., and Hu, S.: Neuro-protective role of IL-4 against activated microglia. J. Immunol., 151: 1473–1481, 1993.PubMedGoogle Scholar
  178. 178.
    Selkoe, D. J.: Amyloid protein and Alzheimer’s disease. Scientific American, 265:No. 5, 68–78, 1991.PubMedGoogle Scholar
  179. 179.
    Yankner, B. A., and Mesulam, M.-M.: β-amyloid and the pathogenesis of Alzheimer’s disease. New Engl. J. Med., 325: 1849–1857, 1991.PubMedGoogle Scholar
  180. 180.
    Hardy, J. A., and Higgins, G. A.: Alzheimer’s disease: the amytoid cascade hypothesis. Science, 256: 184–185, 1992.PubMedGoogle Scholar
  181. 181.
    Regland, B., and Gottfries, C.-G.: The role of amyloid β-protein in Alzheimer’s disease. Lancet, 340: 467–469, 1992.PubMedGoogle Scholar
  182. 182.
    Yoshikawa, K., Aizawa, T., and Hayashi, T.: Degeneration in vitro of post-mitotic neurons over-expressing the alzheimer amyloid protein precursor. Nature, 359: 64–67, 1992.PubMedGoogle Scholar
  183. 183.
    Tanzi, R. E, and Hyman, B. T.: Alzheimer’s mutation. Nature, 350: 564, 1991.PubMedGoogle Scholar
  184. 184.
    Kowall, N. W., Beal, M. F., Busciglio, J., Duffy, L. K., and Yankner, B. A.: An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc. Natl. Acad. Sci. USA, 88: 7247–7251, 1991.Google Scholar
  185. 185.
    Podlisny, M. B., Stephensen, D. T., Frosch, M. P., Tolan, D. R., Lieberburg, I., Clemens, J. A., and Selkoe, D. J.: Microinjection of synthetic amytoid β-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am. J. Pathol., 142: 17–24, 1993.PubMedGoogle Scholar
  186. 186.
    Davies, P.: Neuronal abnormalities, not amyloid, are the cause of dementia in Alzheimer disease, in Alzheimer Disease, edited by Terry, R. D., Katzman, R., and Bick, K. L., New York, Raven Press, 1994, pp. 327–333.Google Scholar
  187. 187.
    Delaere. P., Duyckaerts, C., Masters, C., Beyreuther, K., Piette, F., and Hauw, J-J.: Large amounts of neocortical βA4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci. Lett., 116: 87–93, 1990.PubMedGoogle Scholar
  188. 188.
    Ganrot. P. O.: Metabolism and possible health effects of aluminum. Environ. Health Perspectives, 65: 363–441, 1986.Google Scholar
  189. 189.
    Crapper. D. R., Kruck, T. P., Lukiw, W. J., and Krishnan, S. S.: Would decreased aluminum ingestion reduce the incidence of Alzheimer’s disease? Can. Med. Assoc. J., 145: 793–804, 1991.Google Scholar
  190. 190.
    Klatzo, I., Wisniewski, H., and Streicher, E.: Experimental production of neurofibrillary degeneration: I. Light microscopic observations. J. Neuropathol. Exp. Neurol., 24: 187–199, 1965.PubMedGoogle Scholar
  191. 191.
    Wisniewshi, H., and Terry, R. D.: An experimental approach to the morphogenesis of neurofibrillary degeneration and the argyrophilic plaque, in Alzheimer’sDisease and Related Conditions, edited by Wolstenholme, G. E. W., and O’Connor, M., London, Churchill, 1970, pp. 223–240.Google Scholar
  192. 192.
    Shea, T. B., Clarke, J. F., Wheelock, T. R., Paskevich, P. A., and Nixon, R. A.: Aluminum salts induce the accumulation of neurofilaments in perikarya of NB2a/dl neuroblastoma. Brain Res., 492: 53–64, 1989.PubMedGoogle Scholar
  193. 193.
    Alfrey, A. C., LeGendre, G. R., and Kaehny, W. D.: The dialysis encephalopathy syndrome: possible aluminum intoxication. New Engl. J. Med., 294: 184–188.Google Scholar
  194. 194.
    McDermott, J. R., Smith, A. I., Ward, M. K., Parkinson, S.. and Kerr, D. N. S.: Brain-aluminum concentration in dialysis encephalopathy. Lancet, 1: 901–904, 1978.PubMedGoogle Scholar
  195. 195.
    Scholtz. C. L., Swash, M., Gray, A., Kogeorgos, J. and Marsh, F.: Neurofibrillary neuronal degeneration in dialysis dementia: a feature of aluminum toxicity. Clin. Neuropathol., 6: 93–97, 1987.PubMedGoogle Scholar
  196. 196.
    Roskams, A. J. and Connor, J. R.: Aluminum access to the brain: a role for transferrin and its receptor. Proc. Natl. Acad. Sci. USA, 87: 9024–9027, 1990.PubMedGoogle Scholar
  197. 197.
    Galle, P., Chatel, M., Berry, J.P., and Menault, F.: Encephalopathie myoclonique progressive des dialyes: presence d’aluminium en forte concentration darts les lysosomes des cellules cerebrales. La Nouvelle Presse Med., 8: 4091–4094, 1979.Google Scholar
  198. 198.
    Stekhover, J. H. S., Renkawek, K., Otte-Holler, I., and Stols, A.: Exogenous aluminum accumulates in the lysosomes of cultured rat cortical neurons. Neurosci. Lett., 119: 71–74, 1990.Google Scholar
  199. 199.
    Lovell. M. A., Ehmann, W. D., and Markesberry, W. R.: Laser microprobe analysis of brain aluminum in Alzheimer’s disease. Ann. Neurol., 33: 36–42, 1993.PubMedGoogle Scholar
  200. 200.
    Jacobs. R. W., Duong, T., Jones, R. E., Trapp, G. A., and Scheibl, A. B.: A reexamination of aluminum in Alzheimer’s disease: analysis by energy dispersive X-ray microprobe and flameless atomic absorption spectrophotometry. Can. J. Neurol. Sci., 16: 498–503, 1989.PubMedGoogle Scholar
  201. 201.
    Martyn, C. N., Barker, D. J. P., Osmond, C., Harris, E. C., Edwardson, J. A., and Lacey, R. F.: Geographical relation between Alzheimer’s disease and aluminium in drinking water. Lancet, 1: 59–62. 1989.PubMedGoogle Scholar
  202. 202.
    Sherrard, D. J.: Aluminum-much ado about something. New Eng. J. Med., 324: 558–559, 1991.PubMedGoogle Scholar
  203. 203.
    Editorial: Aluminium and Alzheimer’s disease. Lancet, I: 82–83, 1989.Google Scholar
  204. 204.
    Roberts, G. W., and Clinton, J.: Prion disease: the spectrum of pathology and diagnostic considerations, in Prion Diseases of Human and Animals, edited by Prusiner, S., Collinge, J., Powell, J. and Anderton, B., New York, Ellis Horwood, 1992, pp.215–240.Google Scholar
  205. 205.
    Prusiner, S. B.: Molecular biology of prion diseases. Science, 252: 1515–1522, 1991.PubMedGoogle Scholar
  206. 206.
    Masters, C. L., Gajdusek, D. C., and Gibbs, Jr., C. J.: The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer’s disease. Brain, 104: 535–558, 1981.PubMedGoogle Scholar
  207. 207.
    Prusiner, S. B.: Prions and neurodegenerative diseases. New Engl. J. Med., 317: 1571–1581, 1987.PubMedGoogle Scholar
  208. 208.
    DeArmond, S. J., and Prusiner, S. B.: Etiology and pathogenesis of priori diseases. Amer. J Pathol., 146: 785–811, 1995.Google Scholar
  209. 209.
    Harman, D: Free radical involvement in aging: pathophysiology and therapeutic implications. Drugs & Aging, 3: 60–80, 1993.Google Scholar
  210. 210.
    Harman, D.: Aging: prospects for further increases in the functional life span. Age, 17:119–146, 1994.Google Scholar
  211. 211.
    Bandy, B., and Davison, A. J.: Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radical Biol. Med., 8: 523–539, 1990.Google Scholar
  212. 212.
    Harman, D.: The biologic clock: the mitochondria? J. Am. Geriatr. Soc., 20: 145–147, 1972.PubMedGoogle Scholar
  213. 213.
    Harman, D.: Free radical theory of aging: Consequences of mitochondrial aging. Age, 6: 86–94, 1983.Google Scholar
  214. 214.
    Fleming, J. E., Miquel, J., Cottrell, S. F., Yengoyan, L. S., and Economos, A. C.: Is cell aging caused by respiratory dependent injury to the mitochondrial genome? Gerontology, 28: 44–53, 1982.PubMedGoogle Scholar
  215. 215.
    Nohl, H., and Hegner, D.: Do mitochondria produce oxygen radicals in vivo? Eur. J. Biochem., 82: 863–867, 1978.Google Scholar
  216. 216.
    Nohl, H., Jordan, W., and Hegner, D.: Mitochondrial formation of HO radicals by an ubiquinone-dependent reaction: an alternative pathway to the iron-catalyzed Haber-Weiss cycle. Hoppe-Seyler’s Z. Physiol. Chem., 363: 599–607, 1982.PubMedGoogle Scholar
  217. 217.
    Sohal, R. S., Ku, H-H., Agarwal, S., Forster, M. J., and Lal. H.: Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. Mech. Ageing Develop., 74: 121–133, 1994.Google Scholar
  218. 218.
    Sohal, R. S., and Sohal, B. H.: Hydrogen peroxide release by mitochondria increases during aging. Mech. Ageing Dev., 57: 187–202, 1991.PubMedGoogle Scholar
  219. 219.
    Ku, H.-H., Brunk, U.T., and Sohal, R. S.: Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species. Free Rad. Biol. Med., 15: 621–627, 1993.PubMedGoogle Scholar
  220. 220.
    Ku, H-H., and Sohal, R. S.: Comparison of mitochondrial pro-oxidant generation and anti-oxidant defenses between rat and pigeon: possible basis of variation in longevity and metabolic potential. Mech. Ageing Dev., 72: 67–76, 1993.PubMedGoogle Scholar
  221. 221.
    Barja, G., Cadenas, S., Rojas, C., Perez-Campo, R., and Lopez-Torres, M.: Low mitochondrial free radical production per unit O2 consumption can explain the simultaneous presence of high longevity and high aerobic metabolic rate in birds. Free Rad. Res., 21:317–328, 1994.Google Scholar
  222. 222.
    Yen, T.-C., Chen, Y.-S., King, K.-L., Yeh, S.-H., and Wei, Y.-H.: Liver mitochondrial respiratory functions decline with age. Biochem. Biophys. Res. Commun., 165:994–1003, 1989.Google Scholar
  223. 223.
    Trounce, I., Byme, E., and Marzuki, S.,: Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing. Lancet, 1: 637–639, 1989.PubMedGoogle Scholar
  224. 224.
    Bowling, A. C., Mutisya, E. M., Walker, L. C., Price, D. Cork, L.C., and Beal, M.F.: Age-dependent impairmant of mitochondrial function in primate brain. J. Neurochem., 60: 1964–1967, 1993.PubMedGoogle Scholar
  225. 225.
    Cortopassi, G. A., Shibata, D., Soong, N.-W., and Amheim, N.: A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc. Natl. Acad. Sci. USA, 89: 7370–7374, 1992.PubMedGoogle Scholar
  226. 226.
    Lee, C. M., Chung, S. S., Kaczkowski, J. M., Weindruch, R., and Aiken, J. M.: Multiple mitochondrial DNA deletions associated with age in skeletal muscle of rhesus monkeys. J. Gerontol., Biol.Sci., 48: B201–B205, 1993.Google Scholar
  227. 227.
    Hayakawa, M. Sugiyama, S., Hattori, K., Takasawa, M., and Ozawa, T.: Age-associated damage in mitochondrial DNA in human hearts. Mol. Cell. Biochem., 119: 95–103, 1993.PubMedGoogle Scholar
  228. 228.
    Shoffner, J. M., and Wallace, D. C.: Oxidative phophorylation diseases: disorders of two genomes. Adv. Hum. Genet., 19: 267–330, 1990.PubMedGoogle Scholar
  229. 229.
    Wallace, D.C.: Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science, 256: 628–632 1992.PubMedGoogle Scholar
  230. 230.
    Johns, D. R.: Mitochondrial DNA and disease. N. Engl. J. Med., 333: 638–644, 1995.PubMedGoogle Scholar
  231. 231.
    Harding, A. E.: Neurological disease and mitochondrial genes. Trends Neurot. Sci., 14: 132–138, 1991.Google Scholar
  232. 232.
    Morales, D. T., DiMauro, S., Zeviani, M., et. al.: Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N. Engl. J. Med., 320:1293–1299, 1989.Google Scholar
  233. 233.
    Holt, I. J., Harding, A. E., Cooper, J. M., Schapira, A. H. V., Toscano, A., Clark, J. B., and Morgan-Hughes, J. A.: Mitochondrial myopathics: clincial and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann. Neurol., 26: 699–708, 1989.PubMedGoogle Scholar
  234. 234.
    Rowland, L. P.: Mitochondrial encephalomyopathies: lumping, splitting, and melding, in Mitochondrial Disorders in Neurology, edited by Schapira, A. H. V., and DiMauro, S., Oxford, Butterworth/Heinemann, 1994, pp. 116–129.Google Scholar
  235. 235.
    Luft, R.: The development of mitochondrial medicine. Proc. Natl. Acad. Sci. USA, 91: 8731–8738, 1994.PubMedGoogle Scholar
  236. 236.
    Bowerman, B.: Determinants of blastomere identity in the early C. elegans embryo. BioEssays, 17: 405–414, 1995.PubMedGoogle Scholar
  237. 237.
    Sulston, J. E., Schierenberg, E., White, J. G., and Thomson, J. N.: The embryonic cell lineage of the nematode Caenorhabiditis elegans. Develop. Biol., 100: 64–119, 1983.PubMedGoogle Scholar
  238. 238.
    Kessler, D. S., and Meltog, D. A.: Vertebrate embryonic induction: mesodermal and neural patterning. Science, 266: 596–604, 1994.PubMedGoogle Scholar
  239. 239.
    Shoffner, J. M., Brown, M. D., Torroni, A., Lott, M. T., Cabell, M. F., Mirra, S. S., Beal, M. F., Yang, C.-C., Gearing, M., Salvo, R., Watts, R. L., Juncos, J. L., Hansen, L. A., Crain, B. J., Fayad, M., Reckford, C. L., and Wallace, D. C.: Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics, 17: 171–184, 1993.PubMedGoogle Scholar
  240. 240.
    Lin, F.-H., Lin, R., Wisniewski, H. M., Hwang, Y.-W., Grundke-Iqbal, F., Healy-Louie, G., and Iqbal, K.: Detection of point mutations in codon 331 of mitochondrial NADH dehydrogenase subunit 2 in Alzheimer’s brains. Biochem. Biophys. Res. Commun., 182: 238–246, 1992.PubMedGoogle Scholar
  241. 241.
    Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261: 921–923, 1993.PubMedGoogle Scholar
  242. 242.
    Rebeck, G. W., Reiter, J.S., Strickland, D. K., and Hyman, B. T.: Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron, 11:575–580, 1993.PubMedGoogle Scholar
  243. 243.
    Saunders. A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Periack-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., Hulette, C., Crain, B.. Goldgaber, D., and Roses, A. D.: Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer’s disease. Neurol., 43: 1467–1472, 1993.Google Scholar
  244. 244.
    Gregg, R E..., Zech, L. A., Schaefer, E. J., Stark, D., Wilson, D., and Brewer, Jr., H. W.: Abnormanl in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest., 78: 815–821, 1986.PubMedGoogle Scholar
  245. 245.
    Sherrington, R., Rogaev, E. I., Liang, Y., et. al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Natur, 375: 754–760, 1995.Google Scholar
  246. 246.
    Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmnidt, S. D., Wang, K., Crowley, A. C., Fu, Y.-H., Guenette, S. Y., Galas, D., Nemens. E., Wijsman, E. M., Bird, T. D., Schellenberg, G. D., and Tanzi, R. E.: Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science, 269: 973–977, 1995.PubMedGoogle Scholar
  247. 247.
    L’Hernault, S. W., and Arduengo, P. M.: Mutation of a putative sperm membrane protein in Caenorhabditis elegans prevents sperm differentiation but not its associated meiotic divisions. J. Cell Biol.. 119: 55–68, 1992.PubMedGoogle Scholar
  248. 248.
    Cai, X.-D., Golde, T. E., and Youkin, S. G.: Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science, 259: 514–516, 1993.PubMedGoogle Scholar
  249. 249.
    Higgins. L. D., Rodems, J. M., Catalano, R., Quon, D., and Cordell, B.: Early Alzheimer disease-like histopathology increases in frequency with age in mice transgecic for β-APP751. Proc. Natl. Acad. Sci. USA, 92: 4402–4406, 1995.PubMedGoogle Scholar
  250. 250.
    Moran, P. M., Higgms, L. S., Cordell, B., and Moser, P. C.: Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc. Nat. Acad. Sci. USA, 92: 5341–5345, 1995.PubMedGoogle Scholar
  251. 251.
    Oliver, C., and Holland, A. J.: Down’s syndrome and Alzheimer’s disease: a review. Psychological Med., 16: 307–322, 1986.Google Scholar
  252. 252.
    Rumble. B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., Montgomery, P., Beyreuther, K., and Masters, C. L.: Amyloid A4 protein and its precursor in Down’s syndrome and Alzheimer’s disease. N. Engl. J. Med., 320: 1446–1452, 1988.Google Scholar
  253. 253.
    Wisniewski, K. E., Hill, A. L., and Wisniewski, H. M.: Aging and Alzheimer’s disease in people with Down syndrome, in Down Syndrom: Advances in Medical Care, edited by Lott, I. T., and McCoy, E. E., Wiley-Liss, New York 1992, pp. 167–183.Google Scholar
  254. 254.
    Elroy-Stein, D., and Groner, Y.: Impaired neurotransmitter uptake in PC12 cells overexpressing human Cu/Zn superoxide dismutase-implications for gene dosage effects in Down syndrome. Cell, 52: 259–267, 1988.PubMedGoogle Scholar
  255. 255.
    Elroy-Stein, O., Bernstein, Y., and Gromer, Y.: Overproduction of human Cu/Zn-superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. EMBO J., 5: 615–622, 1986.PubMedGoogle Scholar
  256. 256.
    Zemlan, F.P., Thienhaus, O.J., and Bosmann, H.B.: Superoxide dismutase activity in Alzheimer’s disease: possible mechanism for paired helical filament formation. Brain Res., 476:160–162, 1989.PubMedGoogle Scholar
  257. 257.
    Sinet, P.-M., Lejeune, J., and Jerome, H.: Trisomy 21(Down’s syndrome): glutathione peroxidase, hexose mohophosphate shunt and I. Q. Life Sci., 24: 29–34, 1979.Google Scholar
  258. 258.
    Graves, A. B., White, E., Koepsell, T. D., Reifler, B. V., van Belle, G., Larson, E. B., and Rasking, M.: The association between head traum and Alzheimer’s disease. Am. J. Epidemiol., 131: 491–501, 1990.PubMedGoogle Scholar
  259. 259.
    Roberts, G. W., Allsop, D., and Bruton, C.: The occult aftermath of boxing. J. Neurol. Neurosurg. Psychiat., 53: 373–378, 1990.PubMedGoogle Scholar
  260. 260.
    Guterman, A., and Smith, R. W.: Neurological swquelae of boxing. Sports Med., 4: 194–210, 1987.PubMedGoogle Scholar
  261. 261.
    Roberts, G. W., Gentlemen, S. M., Lynch, A., and Graham, D. I.: βA4 Amyloid protein deposition in brain after head trauma. Lancet, 338: 1422–1423, 1991.PubMedGoogle Scholar
  262. 262.
    Adams, C. W. M., and Bruton, C. J.: the cerebral vasculature in dementia pugilistica. J. Neurol. Neurosurg. Psychiat., 52: 600–6004, 1989.PubMedGoogle Scholar
  263. 263.
    Parker, Jr., W. D., Boysen, S. J., and Parks, J. K.: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann. Neurol., 26: 719–723, 1989.PubMedGoogle Scholar
  264. 264.
    Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., and Scults, C. W.: Low platelet mitochond rial complex I and complex II/III activity in early untreated Parkinson’s disease. Ann. Neurol., 37: 714–722, 1995.PubMedGoogle Scholar
  265. 265.
    Schapira, A.H.V., Cooper, J.M., Dexter, D., Clark, J.B., Jenner, P., and Marsden, C.D.: Mitochondrial Complex I deficiency in Parkinson’s disese. J. Neurochem., 54: 823–827, 1990.PubMedGoogle Scholar
  266. 266.
    Bindoff, L. A., Birch-Machin, M. A., Cartlidge, N. E. F., Parker, Jr., W. D., and Turnbull, D. M.: Respiratory chain abnormalities in skeletal muscle from patients with Parkinson’s disease. J. Neurol. Sci., 104: 203–208, 1991. 265.PubMedGoogle Scholar
  267. 267.
    Ahlqvist, G., Landin, S:, and Wroblewski, R.: Ultrastruture of skeletal muscle in patients with Parkinson’s disease and upper motor lesions. Lab.Invest., 32: 673–679, 1975.PubMedGoogle Scholar
  268. 268.
    Agid, Y.: Parkinson’s disease: pathophysiology. Lancet. 337: 1321–1327, 1991.PubMedGoogle Scholar
  269. 269.
    Braak, H., and Braak, E.: Cognitive impairement in Parkinson’s disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. J. Neural Transm. (P-D Sect), 2: 45–57, 1990.Google Scholar
  270. 270.
    Lennox. G., Lowe, J. S., Godwin-Austen, R. B., Landon, M., and Mayer, R. J.: Diffuse Lewy body disease: an important differential diagnosis in dementia with extrapyramidal features. Prog. Clin. Biol. Res., 317: 121–130, 1989.PubMedGoogle Scholar
  271. 271.
    Harman, D., and Eddy, D. E.,: Free radical theory of aging: beneficial effect of adding antioxidants to the maternal mouse diet on life span of offspring: possible explanation of the sex difference on longevity. Age, 2: 109–122, 1979.Google Scholar
  272. 272.
    Janzen, E. G.: A critical review of spin trapping in biological systems, in Free Radicals in Biology, Vol. 4, edited by Pryor, W. A., New York, Academic Press, 1984, pp. 115–154.Google Scholar
  273. 273.
    Quintanilha, A. T., and Packer, L.: Surface localization of sites of reduction of nitroxide spinlabeled molecules in mitochondria. Proc. Natl. Acad. Sci. USA, 74: 570–574, 1977.PubMedGoogle Scholar
  274. 274.
    Shoffner, J.M., and Wallace, D.C.: Heart disease and mitochondrial DNA mutations. Heart Disease and Stroke, 1: 235–241, 1992.PubMedGoogle Scholar
  275. 275.
    Arts. W. F. M., Scholte, H. R., Bogaard, J. M., Kerrebijn, K. F., Luyt-Houwen, I. E. M.: NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet, 2: 581–582, 1983.PubMedGoogle Scholar
  276. 276.
    Eleff, S., Kennaway, N. G., Buist, N. R. M, Dadey-Usmar, V. M., Capaldi, R. A., Bank, W. J., and Chance, B.: 31P NMR study of improvement in oxidative phosphorylation by vitamin K3 and C in a patient with a defect in electron transport a complex III in skeletal nuscle. Proc. Natl. Acad. Sci., USA, 81: 3529–3533, 1984.PubMedGoogle Scholar
  277. 277.
    Ogasahara, S., Nishikawa, Y., and Yorifuji, S., Soga, F., Nakamura, Y., Takahashi, T., Hashimoto, S., Kono, N., and Taruil S.: Treatment of Kearns-Sayre syndrome with coenzyme Q10. Neurol., 36: 45–53, 1986.Google Scholar

Copyright information

© American Aging Association, Inc. 1995

Authors and Affiliations

  • Denham Harman
    • 1
    • 2
  1. 1.Department of MedicineUniversity of Nebraska College of MedicineOmaha
  2. 2.University of Nebraska College of MedicineOmaha

Personalised recommendations